<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993109</url>
  </required_header>
  <id_info>
    <org_study_id>14511</org_study_id>
    <secondary_id>ADVISE</secondary_id>
    <nct_id>NCT00993109</nct_id>
  </id_info>
  <brief_title>Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension</brief_title>
  <official_title>Randomized,Open-label,Parallel Design Comparator Study of Effect of Nifedipine GITS/OROS (Adalat) 30 mg in Combination With Valsartan (Diovan) 80 mg Compared to Valsartan (Diovan) 160 mg Monotherapy in Patients Whose Blood Pressure is Not Well Controlled by Valsartan 80 mg Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-center, prospective, randomized, open-label, parallel design, two arm
      comparator trial. In the proposed study, the investigators will compare low-dose combination
      therapy of Nifedipine GITS/OROS plus Valsartan with up-titrated monotherapy of Valsartan with
      respect to their blood pressure-decreasing effects in patients with essential
      hypertension.The study consists of a screening visit, followed by randomization and
      administration of either Nifedipine GITS/OROS 30 mg in combination with Valsartan 80 mg or
      Valsartan 160 mg for 12 weeks of treatment.The primary efficacy parameters will be mean SBP
      and DBP on office BP monitoring at 12 weeks of treatment compared to baseline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Systolic BP and Diastolic BP on office Blood Pressure monitoring</measure>
    <time_frame>Baseline and 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (&gt;/=10mmHg decrease of office SBP and &gt;/=5mmHg decrease of office DBP)</measure>
    <time_frame>8 and 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control rate (&lt;/=140/90 of office BP)</measure>
    <time_frame>8 and 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse pressure (difference between SBP and DBP)</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Urinary microalbumin excretion(UAE) in patients with microalbuminuria</measure>
    <time_frame>Baseline and 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event reporting</measure>
    <time_frame>At the start, every 4 weeks during treatment and at the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitals signs</measure>
    <time_frame>At the start, every 4 weeks during treatment and at the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>At the start and at the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalat (Nifedipine, BAYA1040)</intervention_name>
    <description>Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diovan (Valsartan)</intervention_name>
    <description>Valsartan 160 mg OM (Two Valsartan 80mg tablets)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 - 75 years

          -  Essential hypertension not well controlled by current low dose (80 mg) valsartan
             monotherapy for at least 4 weeks. Patients on prior treatment with monotherapy
             diuretic, ACE-I or beta blocker or an ARB other than valsartan and switched to the
             current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible,
             provided the hypertension is still not well controlled.

          -  Office systolic blood pressure (sitting) &gt;140 mmHg (sitting for &gt;/= 5 min., no
             cigarettes and/or coffee/tea for &gt;/=30 min. before BP measurement).

          -  BMI &lt;33 kg/m2

        Exclusion Criteria:

          -  Participation in any clinical investigational drug study within the previous 12 weeks

          -  Concomitant treatments with:

               1. Any anti-hypertensive treatment other than Valsartan 80 mg

               2. Cytochrome P450-3A4 inhibitors or inducers

               3. Potassium-sparing diuretics

          -  Severe hypertension (DBP &gt;/= 110 mm Hg and/or SBP &gt;/= 180 mm Hg) and/or evidence of
             secondary forms of hypertension

          -  Any of the following cardiovascular diseases:

          -  History of cardiovascular shock

          -  Myocardial infarction or unstable angina within the previous 6 months

          -  Severe cardiac valve disease

          -  Past or present severe rhythm or conduction disorder.

          -  Cerebrovascular ischemic event and/or history of intracerebral hemorrhage or
             subarachnoid hemorrhage (SAH) within the previous 12 months

          -  Type 1 or 2 diabetes mellitus

          -  Proteinuria

          -  Uncorrected hypokalemia or hyperkalemia, sodium depletion and/or hypovolemia

          -  Gastrointestinal disease resulting in the potential for malabsorption and/or severe
             gastro-intestinal tract narrowing; kock pouch (ileostomy after proctocolectomy)

          -  Cholestasis or biliary obstruction

          -  Liver disease or aspartate aminotransferase (AST) / alanine aminotransferase (ALT)
             levels &gt;3 x upper limits of normal (ULN)

          -  Renal failure, creatinine level &gt;2.0 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donggu,</city>
        <state>Gwangju Gwang''yeogsi</state>
        <zip>501757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucheon-si,</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yangsan-si</city>
        <state>Gyeongnam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jongno-gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jung-gu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nifedipine GITS/OROS (Adalat®)</keyword>
  <keyword>Valsartan (Diovan®)</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

